Immunotherapy has emerged as a promising adjuvant therapy to improve outcomes in patients with high‐risk neuroblastoma.3 GD2 is a disialoganglioside and promising tumor antigen present in both neuroblastoma and melanoma. This evidence concerns the gene LINC01194 and neuroblastoma.